The recent administration of TKIs as a first-line regimen for ALK-rearranged and EGFR-mutated NSCLC outperformed the platinum-base chemotherapy in terms of response rates, progression-free survival (PFS) and overall survival (OS) [4]. This evidence concerns the gene ALK and non-small cell lung carcinoma.